Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
ID: 358075Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) to support innovative and exploratory research projects in neuroscience. This grant program is designed for early-stage projects that align with the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH), focusing on studies that assess the feasibility of novel investigations with the potential for significant breakthroughs in neuroscience. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and foreign entities, with funding available up to $275,000 over two years. The application period opens on January 16, 2025, with anticipated awards by July 2025; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The Joint NINDS/NIMH Exploratory Neuroscience Research Grant program, issued by the National Institutes of Health (NIH), supports innovative and exploratory research in neuroscience without allowing clinical trials. The program focuses on early-stage projects that could potentially lead to significant advancements in understanding neuroscience or the development of new methodologies. Applicants are advised to ensure their proposals align with the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH) and to consult with relevant program staff before submission. Eligible for funding are various educational institutions, nonprofits, governmental organizations, foreign entities, and small businesses, with awards limited to $275,000 over two years. All applications must adhere to strict submission guidelines, including data management and sharing plans. Key deadlines begin with an application opening on January 16, 2025, and awards anticipated by July 2025. The rigorous review process includes considerations of scientific merit, innovation, and expertise of the investigators. This program underscores NIH's commitment to fostering groundbreaking research in neuroscience while ensuring adherence to regulatory standards and maximizing potential for impactful discoveries.
    Similar Opportunities
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)," aimed at encouraging exploratory research to develop advanced microphysiological systems (MPS) that accurately replicate complex human nervous system architectures. This initiative seeks to facilitate studies on nervous system development, function, and aging, particularly in relation to neurological diseases. The R21 grant allows for a budget of up to $275,000 over two years, with applications opening on January 16, 2025, and a submission deadline of January 7, 2026. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) to support innovative early-stage research projects that may lead to significant advancements in biomedical, behavioral, or clinical fields. This grant is designed to encourage high-risk, high-reward research, providing funding for projects that are distinct from traditional R01 grants, with a maximum budget of $275,000 over a two-year period, and no more than $200,000 in any single year. Eligible applicants include a wide range of organizations such as educational institutions, nonprofit organizations, and tribal governments, with applications undergoing a rigorous peer review process to assess their innovation and feasibility. Interested parties should note that the application submission period begins on January 16, 2025, with the opportunity closing on January 7, 2028; for further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), has announced a funding opportunity titled "NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)" aimed at enhancing research education in biomedical, behavioral, and clinical research. This initiative seeks applications for innovative educational activities that provide hands-on research experiences and skills development, particularly in the field of neuroscience, with a maximum funding of $250,000 per year for up to five years. The program emphasizes diversity recruitment and significant institutional commitment, requiring applicants to include a comprehensive evaluation plan and adhere to strict guidelines. Interested parties can find more information and apply by July 14, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is inviting applications for the Biobehavioral Research Awards for Innovative New Scientists (BRAINS), aimed at supporting early-stage investigators in launching innovative research focused on mental disorders. This program seeks to fund high-risk, high-reward projects that may not have the preliminary data typically required for traditional funding, with an emphasis on advancing understanding and treatment of mental health issues. Eligible applicants include tenure-track faculty designated as Early Stage Investigators by NIH, and the grant provides up to $500,000 per year for a maximum of five years, with a total of approximately $3 million allocated annually for 6-8 awards. Interested parties can find more information and apply by June 20, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that align with NINDS's mission, focusing on innovative approaches to evaluate drugs, devices, and interventions for neurological disorders. The funding is structured as a cooperative agreement with a maximum support period of five years, where the UG3 phase lasts up to two years, followed by a potential transition to the UH3 phase for executing clinical trials. Interested applicants should note that the application process opens on January 10, 2025, with a submission deadline of March 11, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 Clinical Trial Not Allowed grant, aimed at advancing research into the cellular and molecular biology of complex brain disorders. This funding opportunity encourages innovative research focused on high-confidence risk factors associated with conditions such as schizophrenia, major depression, and anxiety, emphasizing hypothesis-generating studies rather than disorder modeling. The grant supports projects with budgets up to $275,000 over a two-year period, with applications due starting January 16, 2025, and a closing date of September 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html.
    BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the BRAIN Initiative for New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21). This initiative invites applications focused on developing innovative technologies to enhance the recording and manipulation of neural activity, particularly at unprecedented scales, while emphasizing the importance of diverse perspectives in the research process. The program aims to advance neuroscience research by addressing critical areas in understanding neural circuits and their functions, with an estimated total program funding of $200,000 and an award ceiling of $200,000 per project. Interested applicants must submit their proposals by June 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25 Clinical Trial Not Allowed)" aimed at fostering a diverse research workforce in neuroscience. This initiative encourages applications from organizations proposing innovative mentoring and professional development activities to support individuals from underrepresented backgrounds in neuroscience research, focusing on enhancing retention and career advancement across various stages. The program is particularly significant for promoting diversity within the scientific workforce, which is essential for enhancing the quality and innovation potential of research. Interested applicants can apply for grants of up to $250,000 annually for a maximum of five years, with the application deadline set for September 26, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-178.html.